SUNPHARMA.NS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 13:00):

Stats
Šios dienos apimtis	1.79M
Vidutinė apimtis	2.82M
Rinkos kapitalizacija	3 614.64B
EPS	INR10.50 ( 2024-01-31 )
Kita pelno data	( INR6.83 ) 2024-05-24
Last Dividend	INR4.00 ( 2023-07-28 )
Next Dividend	INR0 ( N/A )
P/E	40.62
ATR14	INR1.647 (0.11%)

Tūris Koreliacija

Ilgas: 0.42 (neutral)

Trumpas: 0.84 (strong)

Signal:(63.749) Same movement expected

Sun Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Sun Pharmaceutical Koreliacija - Valiuta/Žaliavos

0.42
( neutral )

0.27
( neutral )

-0.57
( weak negative )

0.42
( neutral )

-0.15
( neutral )

0.25
( neutral )

Sun Pharmaceutical Finansinės ataskaitos

Annual	2022
Pajamos:	INR432.79B
Bruto pelnas:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Pajamos:	INR432.79B
Bruto pelnas:	INR326.17B (75.36 %)
EPS:	INR35.32

FY	2022
Pajamos:	INR384.26B
Bruto pelnas:	INR267.19B (69.53 %)
EPS:	INR13.60

FY	2021
Pajamos:	INR334.98B
Bruto pelnas:	INR236.13B (70.49 %)
EPS:	INR12.10

Financial Reports:

No articles found.

Sun Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR3.00 (N/A)	INR0 (N/A)	INR7.50 (N/A)	INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Sun Pharmaceutical Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.54 - low (17.82%) | Divividend Growth Potential Score: 4.46 - Stable (10.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.0208	1996-06-24
Last Dividend	INR4.00	2023-07-28
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	33	--
Total Paid Out	INR59.60	--
Avg. Dividend % Per Year	0.77%	--
Score	2.84	--
Div. Sustainability Score	3.54
Div.Growth Potential Score	4.46
Div. Directional Score	4.00	--

Next Divdend (Est)
(2024-06-03)

INR4.08 Estimate 6.47 %

Dividend Stability

0.26 Very Poor

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1996	INR0	0.00%
1997	INR0	0.00%
1998	INR0	0.00%
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR2.00	0.39%
2019	INR2.75	0.63%
2020	INR4.00	0.92%
2021	INR7.50	1.26%
2022	INR10.00	1.18%
2023	INR11.50	1.15%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
APTUS.NS	Dividend Junior	2023-05-12	Semi-Annually	3	0.32%
TECHNOE.NS	Dividend Junior	2023-09-15	Annually	16	1.13%
ONGC.NS	Dividend Knight	2023-08-18	Semi-Annually	28	4.00%
IOC.NS	Dividend Knight	2023-07-28	Semi-Annually	28	5.08%
CRAFTSMAN.NS	Dividend Junior	2023-06-19	Annually	3	0.13%
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANGCHEFER.NS	Dividend Junior	2023-09-18	Annually	17	1.18%
GRANULES.NS	Dividend Junior	2023-08-03	Semi-Annually	20	0.29%
BAJAJCON.NS	Dividend Junior	2023-08-02	Annually	14	2.26%
TTKPRESTIG.NS	Dividend Junior	2023-07-21	Annually	20	0.43%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.191	1.500	6.18	9.28	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.149	1.500	9.45	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	43.19	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
freeCashFlowPerShareTTM	21.49	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.774	1.000	0.428	0.428	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.23	7.23	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	40.59	1.000	6.00	0	[1 - 100]
returnOnEquityTTM	0.149	2.50	9.65	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	21.49	2.00	2.84	10.00	[0 - 30]
dividendYielPercentageTTM	0.830	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	21.49	2.00	2.84	5.67	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.255	1.500	-1.631	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.110	1.000	9.74	0	[0.1 - 0.5]
Total Score				4.46

Sun Pharmaceutical

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.